European Journal of Cancer Real-time drug testing of paediatric diffuse midline glioma: The Zurich DIPG/DMG centre experience


Children diagnosed with diffuse midline gliomas (DMG) have an extremely poor overall survival: 9–12 months from diagnosis with currently no curative treatment options.


Previous
Previous

Pediatric Neurosurgery Advances and Clinical Trials Update in the Treatment of Diffuse Intrinsic Pontine Gliomas

Next
Next

Neoplasia Journal Interdisciplinary care of children with diffuse midline glioma